A post-operative combination of S-1, an oral fluoropyrimidine-based drug, with endocrine therapy significantly increased invasive…
The international, randomised phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy…
Dong-Xu Liu, Auckland University of Technology According to the latest GLOBOCAN cancer database, New Zealand’s…
I love a good plenary session at ASCO, and this year’s plenary session was one…
Women who have undergone hormonal therapy for breast cancer are at increased risk of developing…
The results of the MONARCH 3 trial, presented at the ESMO 2017 Congress in Madrid,…
Progression-free survival was more than doubled for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast…